Clinical Trials Browser

Terminated × NIH × obinutuzumab × Clear all

NCT03759184 2022-03-22

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Phase 1 Terminated

1 enrolled 13 charts

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia